NASDAQ:MTEM
Molecular Templates Inc Stock News
$1.67
-0.0550 (-3.19%)
At Close: May 03, 2024
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
12:47pm, Thursday, 06'th Feb 2020
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced gra
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
12:43pm, Wednesday, 05'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (N
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
12:51pm, Tuesday, 04'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Bioscie
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int
Molecular Templates Provides Corporate Update and Outlines 2020 Milestones
01:00pm, Wednesday, 08'th Jan 2020
Molecular Templates, Inc., (MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bo
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
02:40am, Monday, 30'th Dec 2019
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FD
Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors
12:00pm, Thursday, 19'th Dec 2019
AUSTIN, Texas, Dec. 19, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s.
Hedge Funds Dropped The Ball On Molecular Templates, Inc. (MTEM)
01:56am, Sunday, 15'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting
03:00pm, Monday, 09'th Dec 2019
AUSTIN, Texas, Dec. 09, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s.
In the money Dec. 2: $49M reported raised
02:09pm, Monday, 02'nd Dec 2019
Check out the latest fundings for Austin companies, including a deal that could be worth more than $500 million for a biotech firm. There's also another seltzer maker in town, spurred on by the founde
Molecular Templates to Present at Two December Investor Conferences
01:00pm, Tuesday, 26'th Nov 2019
AUSTIN, Texas, Nov. 26, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s.
Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering
12:00pm, Thursday, 21'st Nov 2019
Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered
Molecular Templates, Inc. Announces Proposed Public Equity Offering
09:01pm, Wednesday, 20'th Nov 2019
Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered
Vertex Pharmaceuticals Incorporated (VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic re
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
01:00pm, Thursday, 14'th Nov 2019
EDMONTON, Alberta, Nov. 14, 2019 -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient.
